New targets and therapeutic approaches for endocrine malignancies

In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in ear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology & therapeutics (Oxford) Jg. 123; H. 1; S. 117 - 141
Hauptverfasser: Fassnacht, Martin, Kreissl, Michael C., Weismann, Dirk, Allolio, Bruno
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.07.2009
Schlagworte:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Carcinoma
Clinical Trials as Topic
Drug Design
Endocrine Gland Neoplasms - drug therapy
Endocrine Gland Neoplasms - metabolism
Endocrine Gland Neoplasms - pathology
Humans
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
ISSN:0163-7258, 1879-016X, 1879-016X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
ISSN:0163-7258
1879-016X
1879-016X
DOI:10.1016/j.pharmthera.2009.03.013